# Taysha Gene Therapies, Inc.: financial statements, quarterly

TSHA · Nasdaq · CIK 1806310 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tsha.md) · [Financials](/companies/tsha/financials.md) · [Filings](/companies/tsha/filings.md) · [Insiders](/companies/tsha/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tsha/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.7](/filings/0000950170-24-126416.md) | [3.6 d](/filings/0000950170-25-027348.md) | [3.4](/filings/0000950170-25-072036.md) | [1.1](/filings/0000950170-25-107010.md) | [1.8](/filings/0001193125-25-263506.md) | [2.0 d](/filings/0001193125-26-115202.md) | [2.3](/filings/0001193125-26-207666.md) | [2.0](/filings/0001193125-26-344610.md) | [0.0](/filings/0001193125-25-263506.md) | [5.5 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [0.0](/filings/0001193125-26-344610.md) |
| Research and development | $m | [11.8](/filings/0000950170-24-126416.md) | [12.7 d](/filings/0000950170-25-027348.md) | [20.7](/filings/0000950170-25-072036.md) | [15.1](/filings/0000950170-25-107010.md) | [14.9](/filings/0001193125-25-263506.md) | [15.3 d](/filings/0001193125-26-115202.md) | [15.6](/filings/0001193125-26-207666.md) | [20.1](/filings/0001193125-26-344610.md) | [25.7](/filings/0001193125-25-263506.md) | [25.0 d](/filings/0001193125-26-115202.md) | [33.8](/filings/0001193125-26-207666.md) | [38.6](/filings/0001193125-26-344610.md) |
| Operating income | $m | [(16.3)](/filings/0000950170-24-126416.md) | [(16.2) d](/filings/0000950170-25-027348.md) | [(24.3)](/filings/0000950170-25-072036.md) | [(21.3)](/filings/0000950170-25-107010.md) | [(25.9)](/filings/0001193125-25-263506.md) | [(19.9) d](/filings/0001193125-26-115202.md) | [(21.4)](/filings/0001193125-26-207666.md) | [(26.8)](/filings/0001193125-26-344610.md) | [(34.0)](/filings/0001193125-25-263506.md) | [(28.3) d](/filings/0001193125-26-115202.md) | [(43.5)](/filings/0001193125-26-207666.md) | [(47.3)](/filings/0001193125-26-344610.md) |
| Interest expense | $m | [1.5](/filings/0000950170-23-063734.md) | [0.7 d](/filings/0000950170-24-033484.md) | [0.0](/filings/0000950170-24-059555.md) | [0.0](/filings/0000950170-24-095082.md) | [0.0](/filings/0001193125-25-263506.md) | [0.0 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [0.0](/filings/0001193125-26-344610.md) | [0.0](/filings/0001193125-25-263506.md) | [0.0 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [0.0](/filings/0001193125-26-344610.md) |
| Income tax | $m | [0.0 d](/filings/0000950170-23-063734.md) | [0.0 d](/filings/0000950170-24-033484.md) | [0.0](/filings/0000950170-24-059555.md) | [0.0 d](/filings/0000950170-24-095082.md) | [0.0 d](/filings/0000950170-24-126416.md) | [0.0 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0000950170-25-072036.md) | [0.0 d](/filings/0000950170-25-107010.md) | [0.0 d](/filings/0001193125-25-263506.md) | [0.0 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [0.0 d](/filings/0001193125-26-344610.md) |
| Net income | $m | [(117)](/filings/0000950170-24-126416.md) | [47.7 d](/filings/0000950170-25-027348.md) | [(24.1)](/filings/0000950170-25-072036.md) | [(20.9)](/filings/0000950170-25-107010.md) | [(25.5)](/filings/0001193125-25-263506.md) | [(18.8) d](/filings/0001193125-26-115202.md) | [(21.5)](/filings/0001193125-26-207666.md) | [(26.9)](/filings/0001193125-26-344610.md) | [(32.7)](/filings/0001193125-25-263506.md) | [(27.9) d](/filings/0001193125-26-115202.md) | [(42.4)](/filings/0001193125-26-207666.md) | [(46.6)](/filings/0001193125-26-344610.md) |
| Diluted EPS | $ per share | [(0.93)](/filings/0000950170-24-126416.md) | not reported | [(0.10)](/filings/0000950170-25-072036.md) | [(0.09)](/filings/0000950170-25-107010.md) | [(0.10)](/filings/0001193125-25-263506.md) | not reported | [(0.08)](/filings/0001193125-26-207666.md) | [(0.09)](/filings/0001193125-26-344610.md) | [(0.09)](/filings/0001193125-25-263506.md) | not reported | [(0.12)](/filings/0001193125-26-207666.md) | [(0.13)](/filings/0001193125-26-344610.md) |
| Basic EPS | $ per share | [(0.93)](/filings/0000950170-24-126416.md) | not reported | [(0.10)](/filings/0000950170-25-072036.md) | [(0.09)](/filings/0000950170-25-107010.md) | [(0.10)](/filings/0001193125-25-263506.md) | not reported | [(0.08)](/filings/0001193125-26-207666.md) | [(0.09)](/filings/0001193125-26-344610.md) | [(0.09)](/filings/0001193125-25-263506.md) | not reported | [(0.12)](/filings/0001193125-26-207666.md) | [(0.13)](/filings/0001193125-26-344610.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [164](/filings/0000950170-24-126416.md) | [144](/filings/0000950170-25-027348.md) | [124](/filings/0000950170-25-072036.md) | [173](/filings/0000950170-25-107010.md) | [158](/filings/0001193125-25-263506.md) | [139](/filings/0001193125-26-115202.md) | [117](/filings/0001193125-26-207666.md) | [313](/filings/0001193125-26-344610.md) | [297](/filings/0001193125-25-263506.md) | [320](/filings/0001193125-26-344610.md) | [277](/filings/0001193125-26-207666.md) | [455](/filings/0001193125-26-344610.md) |
| Current assets | $m | [172](/filings/0000950170-23-063734.md) | [150](/filings/0000950170-25-027348.md) | [131](/filings/0000950170-24-059555.md) | [178](/filings/0000950170-24-095082.md) | [162](/filings/0000950170-24-126416.md) | [142](/filings/0001193125-26-115202.md) | [121](/filings/0000950170-25-072036.md) | [316](/filings/0000950170-25-107010.md) | [300](/filings/0001193125-25-263506.md) | [325](/filings/0001193125-26-344610.md) | [282](/filings/0001193125-26-207666.md) | [461](/filings/0001193125-26-344610.md) |
| Total assets | $m | [196](/filings/0000950170-23-063734.md) | [173](/filings/0000950170-25-027348.md) | [153](/filings/0000950170-24-059555.md) | [200](/filings/0000950170-24-095082.md) | [180](/filings/0000950170-24-126416.md) | [160](/filings/0001193125-26-115202.md) | [138](/filings/0000950170-25-072036.md) | [333](/filings/0000950170-25-107010.md) | [317](/filings/0001193125-25-263506.md) | [343](/filings/0001193125-26-344610.md) | [300](/filings/0001193125-26-207666.md) | [470](/filings/0001193125-26-344610.md) |
| Current liabilities | $m | [180](/filings/0000950170-23-063734.md) | [36.8](/filings/0000950170-25-027348.md) | [38.6](/filings/0000950170-24-059555.md) | [34.2](/filings/0000950170-24-095082.md) | [29.3](/filings/0000950170-24-126416.md) | [26.2](/filings/0001193125-26-115202.md) | [22.6](/filings/0000950170-25-072036.md) | [25.3](/filings/0000950170-25-107010.md) | [28.6](/filings/0001193125-25-263506.md) | [26.6](/filings/0001193125-26-344610.md) | [20.1](/filings/0001193125-26-207666.md) | [26.0](/filings/0001193125-26-344610.md) |
| Total liabilities | $m | [245](/filings/0000950170-23-063734.md) | [97.8](/filings/0000950170-25-027348.md) | [99.2](/filings/0000950170-24-059555.md) | [91.5](/filings/0000950170-24-095082.md) | [91.4](/filings/0000950170-24-126416.md) | [88.8](/filings/0001193125-26-115202.md) | [83.3](/filings/0000950170-25-072036.md) | [84.6](/filings/0000950170-25-107010.md) | [97.6](/filings/0001193125-25-263506.md) | [96.4](/filings/0001193125-26-344610.md) | [88.4](/filings/0001193125-26-207666.md) | [83.2](/filings/0001193125-26-344610.md) |
| Long-term debt | $m | [38.5](/filings/0000950170-23-063734.md) | [40.5](/filings/0000950170-25-027348.md) | [40.5](/filings/0000950170-24-059555.md) | [37.8](/filings/0000950170-24-095082.md) | [43.0](/filings/0000950170-24-126416.md) | [43.9](/filings/0001193125-26-115202.md) | [42.5](/filings/0000950170-25-072036.md) | [41.1](/filings/0000950170-25-107010.md) | [50.9](/filings/0001193125-25-263506.md) | [50.1](/filings/0001193125-26-344610.md) | [49.0](/filings/0001193125-26-207666.md) | [49.3](/filings/0001193125-26-344610.md) |
| Shareholders' equity | $m | [(49.1)](/filings/0000950170-24-126416.md) | [74.9](/filings/0001193125-26-115202.md) | [53.8](/filings/0000950170-25-107010.md) | [109](/filings/0001193125-25-263506.md) | [88.8](/filings/0001193125-25-263506.md) | [71.5](/filings/0001193125-26-344610.md) | [55.1](/filings/0001193125-26-344610.md) | [249](/filings/0001193125-26-344610.md) | [219](/filings/0001193125-25-263506.md) | [247](/filings/0001193125-26-344610.md) | [212](/filings/0001193125-26-344610.md) | [387](/filings/0001193125-26-344610.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.9) d](/filings/0000950170-24-126416.md) | [(16.1) d](/filings/0000950170-25-027348.md) | [(19.8)](/filings/0000950170-25-072036.md) | [(21.5) d](/filings/0000950170-25-107010.md) | [(21.6) d](/filings/0001193125-25-263506.md) | [(18.3) d](/filings/0001193125-26-115202.md) | [(22.0)](/filings/0001193125-26-207666.md) | [(20.2) d](/filings/0001193125-26-344610.md) | [(24.2) d](/filings/0001193125-25-263506.md) | [(26.7) d](/filings/0001193125-26-115202.md) | [(40.9)](/filings/0001193125-26-207666.md) | [(40.4) d](/filings/0001193125-26-344610.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-126416.md) | [0.0 d](/filings/0000950170-25-027348.md) | [0.1](/filings/0000950170-24-059555.md) | [0.2 d](/filings/0000950170-25-107010.md) | [0.0 d](/filings/0001193125-25-263506.md) | [(0.0) d](/filings/0001193125-26-115202.md) | [0.4](/filings/0001193125-26-207666.md) | [0.0 d](/filings/0001193125-26-344610.md) | [0.1 d](/filings/0001193125-25-263506.md) | [0.3 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [(0.0) d](/filings/0001193125-26-344610.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.9](/filings/0000950170-23-063734.md) | [63.3](/filings/0000950170-24-059555.md) | [64.2](/filings/0000950170-24-095082.md) | [126](/filings/0000950170-24-126416.md) | [231](/filings/0000950170-25-072036.md) | [233](/filings/0000950170-25-107010.md) | [268](/filings/0001193125-25-263506.md) | [269](/filings/0001193125-26-207666.md) | [298](/filings/0001193125-26-344610.md) | [353](/filings/0001193125-25-263506.md) | [367](/filings/0001193125-26-207666.md) | [369](/filings/0001193125-26-344610.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 325,833,545 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344610.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.